Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

NCT03387761 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT03387761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03387761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
January 15, 2018
Completion date
January 7, 2025
Enrollment
54 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

urothelial carcinoma